Press Releases

Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Mark Genovese, MD, has been appointed Senior Vice President, Inflammation, with responsibility for overseeing the clinical development of the company’s investigational portfolio of treatments for inflammatory conditions.

Dr. Genovese, who has already begun his new role, comes to the company from Stanford University, where he was on the faculty for more than 21 years and most recently served as the James W. Raitt Professor of Medicine and Clinical Chief in the Division of Immunology and Rheumatology. At Stanford, he established a clinical research program focused on translational medicine in autoimmune diseases and led numerous investigator-initiated studies and international multi-center trials for the treatment of rheumatological diseases, including arthritis. He received his undergraduate degree from the University of Notre Dame and his medical degree from the Johns Hopkins University School of Medicine. Dr. Genovese will report to Merdad Parsey, MD, PhD, Chief Medical Officer.

Gilead is expanding its work in the field of inflammatory diseases, with the goal of advancing new products for patients in an area where, despite having approved therapies, significant need for new treatment remains. Gilead has filed for regulatory approval in the United States, Europe and Japan of a potential treatment for rheumatoid arthritis (RA), which, if approved, would be the company’s first medicine to treat an inflammatory disease. Gilead is focused on expanding its work across a broad range of inflammatory conditions with the goal of helping physicians and people with inflammatory diseases reach their treatment goals. Dr. Genovese will also have responsibility for the company’s fibrosis clinical research programs including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis and systemic sclerosis.

“We are very pleased to welcome Mark to Gilead – he is one of the leading researchers and clinicians in the fields of immunology and rheumatology, and we will benefit tremendously from his expertise as we seek to bring forward new treatments that improve care for patients with rheumatoid arthritis, inflammatory bowel disease and other debilitating conditions,” said Dr. Parsey. “The company has set the ambitious goal of introducing 10 transformative medicines over the next decade and I believe that Mark’s appointment will help us significantly advance our work in inflammation.”

“Gilead has a long history of transforming care for people with serious illnesses, such as HIV and viral hepatitis, and I’ve watched as the company has worked over the past several years to add programs, resources and individuals to bring that same scientific rigor and innovation to patients with inflammatory diseases, where doctors and patients are so much in need of better treatment options,” commented Dr. Genovese. “In my prior academic role, I had the opportunity to work with Gilead as the company began to grow its work in inflammatory diseases, and I’m excited to join the talented team. I look forward to the progress we will make together to transform care for patients.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Doug Maffei, PhD, Investors
(650) 522-2739

Marni Kottle, Media
(650) 522-5388

Source: Gilead Sciences, Inc.